Savara (NASDAQ:SVRA) Stock Price Down 6.6%

Shares of Savara Inc (NASDAQ:SVRA) were down 6.6% during trading on Wednesday . The company traded as low as $4.38 and last traded at $4.38. Approximately 242,565 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 837,078 shares. The stock had previously closed at $4.69.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SVRA shares. JMP Securities reissued a “market outperform” rating and issued a $8.00 target price on shares of Savara in a report on Thursday, April 18th. Piper Sandler increased their target price on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $8.20.

Savara Trading Down 0.9 %

The company has a market cap of $609.24 million, a price-to-earnings ratio of -13.36 and a beta of 0.77. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The firm’s 50-day moving average price is $4.92 and its 200 day moving average price is $4.43.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, equities analysts expect that Savara Inc will post -0.38 EPS for the current year.

Institutional Trading of Savara

Several large investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System lifted its holdings in shares of Savara by 19.1% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 25,780 shares of the company’s stock worth $97,000 after purchasing an additional 4,140 shares in the last quarter. AJOVista LLC bought a new position in shares of Savara in the 4th quarter worth $40,000. Principal Financial Group Inc. bought a new position in shares of Savara in the 3rd quarter worth $48,000. SG Americas Securities LLC lifted its holdings in shares of Savara by 34.2% in the 4th quarter. SG Americas Securities LLC now owns 49,862 shares of the company’s stock worth $234,000 after purchasing an additional 12,720 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Savara in the 4th quarter worth $74,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.